IL21 and neoplasm: In a comparable preclinical study, Amgen Inc. developed a highly attenuated variant of IL-21 (R9E:R76A) and fused it to an anti-PD-1 antibody, and it provided protection against a humanized mouse tumor model that was resistant to anti-PD-1 monotherapy (125).